Our vision is to “deliver affinity ligands based on either DNA, peptides or mixed mode to your targets in less than a week”. We intend to establish a great impact on development speed in therapeutics, diagnostis and separation of biomolecules creating biomarkers in a couple of days. A4 has started an internal program for making custom purfication “resins”. However the company will support anyone in the field of separations with product and business development. We believe that creating strong networks will increase our value to customers and accelerate the realization of our vision.
Jacques Clemens B.Sc., owner of A4 combines practical experiences in R&D (immunology) and international sales+management of bio-separation solutions. He worked as sales director for Amersham Pharmacia Biotech (GE Healthcare) and Pall Lifesciences and as vice president for Asahi Kasei Bioprocess selling chromatography, filtration and virus removal applications plus engineering solutions for the same. Most of these projects were highly customised, differing significantly for each client. Jacques founded A4 in 2013 to explore the potential of aptamers replacing antibodies and has built a solid network to deliver affinity products for various purposes.
From a long standing background in chemical purifiers for pharmaceutical manufacturers A4 Lifesciences boasts a broad knowledge of the subject field, ongoing developments and players in the market.
A4 develops high affinity aptamer based small molecular binders at a client request through it’s operational network. It also acts as consultant or broker for R&D and commercial purposes in the same field of operation.
A4 Lifesciences has the specialities and connections to go beyond the research and preparatory stages of creating biomarkers or affinity resins for purification. Additionaly A4 can organise scaled production together with carefully selected partners .
The aim of this project was to find high affinity selective binders and discover the best route from aptamer selection (SELEX) to a binder suitable for purification of IgG from clarified cell culture. A4 specified the target and physiological requirements to the aptamer WRT binding, elution and cleaning. Aptamer binder candidates and positive and negative controls have been synthesised, including a variety of spacers. Aptamers have been tested by SPR, SPRi and Isothermal calorimetry.
Establish aptamers in one week with the long term aim to make it as short as one day. Conglomerate consists of all companies required to select and test aptamers, to conjugate, immobilise aptamers, validate the final product and to commercialise the product. A4 lifesciences is co-writer of the application and has the roles: project coordination, making an aptamer-resin and marketing of the product. The conglomerate parties endeavour to bring this supply chain to the market together.
This project developed a pre- and post-integrity test that combined filter bubble point test and Gold Particle Test. The challenge of the project was to implement the manual integrity operations of the client and to match those with validation requirement specifications set by the filter manufacturer. The role in the project was to bridge the client requirements and wishes with the capabilities of the supplier to a win-win situation. The fit for purpose system saved significant time to the client compared to the old situation, while supplier got a well-tested new standard system supported by a good user reference.
A4 has ample experiences from working for industry leaders in the field of chromatography, ultra-filtration and depth filtration and virus removal filtration. By running numerous projects in biopharmacy, a unique capability has been developed that combines application development with practical engineering solutions. This encompasses team driven product and process development as well as commercial implementations.
It is commonly spoken of that many complex projects do not meet up to expectations. Failure is often thought to be caused by issues from within project management like planning, communication and scope creep. However projects are deemed to fail if they are not lined up with vision, strategy, changing invironments or suffer from misinterpretations of the current situation.
A4 can review your existing projects or advise you on new projects. We can be an extra set of eyes or the third party who has a fresh perspective on the project. A4 uses internal R&D and business experience and engages a wide network as required for the case.
A4 can help you finding the best ligand for purpose through its network. It can either be DNA or peptide based, or the two are compared. Affinity molecules can be supplied tested for purpose, but we can also run the project together with you. Synthesis and spacers for coupling are addressed and so are resins/polymers that suite your circumstances best.
We aim at bringing the lead time of fully tested affinity molecules down to a couple of days while keeping costs to a fair minimum. This process is still in a concept phase for which we are looking for test partners.